vs
Side-by-side financial comparison of Pacira BioSciences, Inc. (PCRX) and TOMPKINS FINANCIAL CORP (TMP). Click either name above to swap in a different company.
TOMPKINS FINANCIAL CORP is the larger business by last-quarter revenue ($194.8M vs $177.4M, roughly 1.1× Pacira BioSciences, Inc.). TOMPKINS FINANCIAL CORP runs the higher net margin — 49.4% vs 1.6%, a 47.8% gap on every dollar of revenue. On growth, TOMPKINS FINANCIAL CORP posted the faster year-over-year revenue change (152.7% vs 5.0%). Over the past eight quarters, TOMPKINS FINANCIAL CORP's revenue compounded faster (63.6% CAGR vs -0.2%).
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
Tompkins Financial Corporation is a small, diversified financial services company based in Ithaca, New York. It is the parent of the Tompkins Trust Company, as well as several other banks, an insurance agency, and a wealth management division.
PCRX vs TMP — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $177.4M | $194.8M |
| Net Profit | $2.9M | $96.2M |
| Gross Margin | — | — |
| Operating Margin | 3.9% | 71.7% |
| Net Margin | 1.6% | 49.4% |
| Revenue YoY | 5.0% | 152.7% |
| Net Profit YoY | — | 388.9% |
| EPS (diluted) | $0.07 | $6.72 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $177.4M | — | ||
| Q4 25 | $196.9M | $194.8M | ||
| Q3 25 | $179.5M | $87.4M | ||
| Q2 25 | $181.1M | $82.6M | ||
| Q1 25 | $168.9M | $81.7M | ||
| Q4 24 | $187.3M | $77.1M | ||
| Q3 24 | $168.6M | $76.6M | ||
| Q2 24 | $178.0M | $72.7M |
| Q1 26 | $2.9M | — | ||
| Q4 25 | — | $96.2M | ||
| Q3 25 | $5.4M | $23.7M | ||
| Q2 25 | $-4.8M | $21.5M | ||
| Q1 25 | $4.8M | $19.7M | ||
| Q4 24 | — | $19.7M | ||
| Q3 24 | $-143.5M | $18.6M | ||
| Q2 24 | $18.9M | $15.7M |
| Q1 26 | — | — | ||
| Q4 25 | 79.5% | — | ||
| Q3 25 | 80.9% | — | ||
| Q2 25 | 77.4% | — | ||
| Q1 25 | 79.7% | — | ||
| Q4 24 | 78.7% | — | ||
| Q3 24 | 76.9% | — | ||
| Q2 24 | 75.1% | — |
| Q1 26 | 3.9% | — | ||
| Q4 25 | 1.2% | 71.7% | ||
| Q3 25 | 3.5% | 35.6% | ||
| Q2 25 | 4.7% | 34.2% | ||
| Q1 25 | 1.2% | 31.6% | ||
| Q4 24 | 13.2% | 33.4% | ||
| Q3 24 | -82.8% | 32.0% | ||
| Q2 24 | 15.9% | 28.3% |
| Q1 26 | 1.6% | — | ||
| Q4 25 | — | 49.4% | ||
| Q3 25 | 3.0% | 27.1% | ||
| Q2 25 | -2.7% | 26.0% | ||
| Q1 25 | 2.8% | 24.1% | ||
| Q4 24 | — | 25.5% | ||
| Q3 24 | -85.1% | 24.3% | ||
| Q2 24 | 10.6% | 21.6% |
| Q1 26 | $0.07 | — | ||
| Q4 25 | $0.05 | $6.72 | ||
| Q3 25 | $0.12 | $1.65 | ||
| Q2 25 | $-0.11 | $1.50 | ||
| Q1 25 | $0.10 | $1.37 | ||
| Q4 24 | $0.38 | $1.39 | ||
| Q3 24 | $-3.11 | $1.30 | ||
| Q2 24 | $0.39 | $1.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $144.3M | $132.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $653.9M | $938.4M |
| Total Assets | $1.2B | $8.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $144.3M | — | ||
| Q4 25 | $238.4M | $132.8M | ||
| Q3 25 | $246.3M | $193.5M | ||
| Q2 25 | $445.9M | $212.6M | ||
| Q1 25 | $493.6M | $193.1M | ||
| Q4 24 | $484.6M | $134.4M | ||
| Q3 24 | $453.8M | $132.3M | ||
| Q2 24 | $404.2M | $70.9M |
| Q1 26 | — | — | ||
| Q4 25 | $372.2M | — | ||
| Q3 25 | $376.7M | — | ||
| Q2 25 | $580.5M | — | ||
| Q1 25 | $583.4M | — | ||
| Q4 24 | $585.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $653.9M | — | ||
| Q4 25 | $693.1M | $938.4M | ||
| Q3 25 | $727.2M | $788.8M | ||
| Q2 25 | $757.8M | $761.8M | ||
| Q1 25 | $798.5M | $741.4M | ||
| Q4 24 | $778.3M | $713.4M | ||
| Q3 24 | $749.6M | $719.9M | ||
| Q2 24 | $879.3M | $674.6M |
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.3B | $8.7B | ||
| Q3 25 | $1.3B | $8.5B | ||
| Q2 25 | $1.5B | $8.4B | ||
| Q1 25 | $1.6B | $8.2B | ||
| Q4 24 | $1.6B | $8.1B | ||
| Q3 24 | $1.5B | $8.0B | ||
| Q2 24 | $1.6B | $7.9B |
| Q1 26 | — | — | ||
| Q4 25 | 0.54× | — | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $38.9M |
| Free Cash FlowOCF − Capex | — | $31.9M |
| FCF MarginFCF / Revenue | — | 16.4% |
| Capex IntensityCapex / Revenue | — | 3.6% |
| Cash ConversionOCF / Net Profit | — | 0.40× |
| TTM Free Cash FlowTrailing 4 quarters | — | $105.0M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $43.7M | $38.9M | ||
| Q3 25 | $60.8M | $34.9M | ||
| Q2 25 | $12.0M | $18.9M | ||
| Q1 25 | $35.5M | $22.2M | ||
| Q4 24 | $33.1M | $95.0M | ||
| Q3 24 | $53.9M | $21.2M | ||
| Q2 24 | $53.2M | $27.3M |
| Q1 26 | — | — | ||
| Q4 25 | $43.5M | $31.9M | ||
| Q3 25 | $57.0M | $33.9M | ||
| Q2 25 | $9.3M | $18.3M | ||
| Q1 25 | $26.9M | $20.9M | ||
| Q4 24 | $31.0M | $88.8M | ||
| Q3 24 | $49.8M | $18.9M | ||
| Q2 24 | $51.6M | $26.3M |
| Q1 26 | — | — | ||
| Q4 25 | 22.1% | 16.4% | ||
| Q3 25 | 31.7% | 38.8% | ||
| Q2 25 | 5.1% | 22.1% | ||
| Q1 25 | 15.9% | 25.5% | ||
| Q4 24 | 16.6% | 115.1% | ||
| Q3 24 | 29.6% | 24.7% | ||
| Q2 24 | 29.0% | 36.2% |
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 3.6% | ||
| Q3 25 | 2.2% | 1.1% | ||
| Q2 25 | 1.5% | 0.8% | ||
| Q1 25 | 5.1% | 1.7% | ||
| Q4 24 | 1.1% | 8.1% | ||
| Q3 24 | 2.4% | 2.9% | ||
| Q2 24 | 0.9% | 1.3% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.40× | ||
| Q3 25 | 11.20× | 1.47× | ||
| Q2 25 | — | 0.88× | ||
| Q1 25 | 7.37× | 1.13× | ||
| Q4 24 | — | 4.82× | ||
| Q3 24 | — | 1.14× | ||
| Q2 24 | 2.82× | 1.74× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
TMP
Segment breakdown not available.
